43results about How to "High diagnostic sensitivity" patented technology

Methods and systems are provided for diagnosing each of a plurality of engine cooling system components including various valves and grill shutters. Each valve may be individually closed and opened for a specified duration, and corresponding changes in coolant temperature may be monitored. If all the components are functional, the various valves may be adjusted to stagnate coolant at the engine and expedite engine warm-up during a cold-start.

An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and / or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and / or free radicals and / or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

Optical data is obtained from a pair of breasts, employing a simultaneous bilateral referencing protocol, and is subsequently analyzed employing a self-referencing data analysis method. Optical measurements can be performed on both breasts simultaneously under various protocols, including resting-state measures and evoked responses. Sensing hardware and data collection protocols are economical and can be implemented without patient discomfort. The natural variance inherently associated with optical measures of the breast is reduced by: imposition of substantially symmetric boundary conditions; collection of simultaneous bilateral dynamic measures; referencing measurement data of one breast to measurement data from another.

Methods and systems are provided for diagnosing each of a plurality of engine cooling system components including various valves and grill shutters. Each valve may be individually closed and opened for a specified duration, and corresponding changes in coolant temperature may be monitored. If all the components are functional, the various valves may be adjusted to stagnate coolant at the engine and expedite engine warm-up during a cold-start.

The invention provides a method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising: (i) contacting T-cells from said human with one or more of (a) a peptide having the sequence shown in SEQ ID NO: 1; (b) a peptide having or comprising the sequence of at least 8 consecutive amino acids of the sequence shown in SEQ ID NO: 1; or (c) a peptide having or comprising a sequence which is capable of binding to a T-cell receptor which recognizes a peptide as defined in (a) or (b); and (ii) determining whether any of the said T-cells recognize said peptide, wherein steps (i) and (ii) are optionally carried out in vitro.

The invention discloses a turbo-generator excitation winding turn-to-turn short circuit fault diagnosis method. The method comprises the following steps: 1) a generator finite element model is established, and a rotor fundamental frequency vibration and a phase angle caused by different excitation winding turn-to-turn short circuit faults are calculated to serve as a sample set of fault diagnosis;and 2) rotor vibration data during operation of the generator is collected online and in real time, the correlation degree between the vibration data and the fault sample set is obtained, and the fault degree and the fault position of the excitation winding turn-to-turn short circuit are obtained. According to the turbo-generator excitation winding turn-to-turn short circuit fault diagnosis method provided by the invention, according to the influence of electromagnetic and heat imbalance caused by the excitation winding turn-to-turn short circuit faults on the vibration of the rotor, the vibration characteristic is extracted, good diagnosis sensitivity is achieved, a new detection device does not need to be installed, thereby improving the fault diagnosis efficiency, and the method has the advantages of being simple and easy to implement and high in reliability.

The invention discloses a reagent kit for detecting cancer-related DNA methylation and application of the reagent kit for detecting cancer-related DNA methylation. The invention provides the application of the substances for detecting CCGG site methylation levels of RASSF1A gene, OPCML gene and HOXA9 gene in the promoter region of the genome of the sample to be detected in the preparation of products for identifying or assisting identification whether the sample to be detected is a cancer sample. Experiments prove that the method and the promoter of the reagent kit for detecting cancer-related DNA methylation are capable of identifying whether the sample to be tested is a cancer sample or whether the subject to be tested is a cancer patient, so that a single sample can be timely and accurately identified; compared with the detection of methylation status of a single gene, the reagent kit for detecting cancer-related DNA methylation has higher diagnostic sensitivity and better specificity; moreover, the statistic analysis and the cumulative analyses are replaced by threshold values, so that instant diagnosis of cancer can be more likely realized.

The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention relates to a process for the in vitro determination of antibodies, wherein the peptides used are biotinylated, particularly in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides.

The invention relates to a hydrothorax fluid metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The hydrothorax fluid metabolite combination for diagnosing tuberculous pleurisy comprises dimethylglycine, tyrosine, kynurenine, nicotinamide, betaine, acylcarnitine with the ratio of 12: 0, acylcarnitine with the ratio of 14: 2 and phosphatidylcholine with the ratio of 42:8. The kit for diagnosing tuberculous pleurisy comprises an internal standard substance required for detecting the concentrations of dimethylglycine, tyrosine, kynurenine, nicotinamide, betaine, acylcarnitine with the ratio of 12: 0, acylcarnitine with the ratio of 14: 2 and phosphatidylcholine with the ratio of 42: 8 in a pleural effusion sample extraction solution. A combined marker provided bythe invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, meanwhile, can be complementary with the traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

The invention relates to a novel application of small molecule metabolites glucose-6-phosphoric acid, erythritol 4-phosphoric acid, xanthine and phosphatidylcholine PC (33:1) in a tissue sample as a combined metabolic marker in preparation of a kit for diagnosing patients with lung cancer and lung benign nodules in subjects. The invention further relates to a kit for detecting the lung cancer and lung benign nodule patients in subjects. By detecting the relative concentrations of the combined markers in tissue samples of the subjects, the variable P value of the combined markers is calculated on the basis of a binary logistic regression equation, and then based on a determined cut-off value, the patients with lung cancer and lung benign nodules are diagnosed. In addition, the combined marker also has better diagnostic ability for patients with early lung cancer and lung benign nodules. The kit can realize high-sensitivity and high-efficiency detection of several small molecule metabolites involved in the invention, and has the characteristics of low detection cost and good repeatability.

The present invention discloses the use of Mycobacterium tuberculosis antigens for use in in vivodetermination of the presence of Mtbinfection in immunocompromised persons or persons co-infected with HIVand the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtbinfection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.

The present invention relates to an application of amine metabolites in serum: aspartic acid, ornithine, hypoxanthine, phenylalanyl phenylalanine and glutamine phenylalanine as combination markers in preparation of a kit for early hepatic encephalopathy paints for diagnosis subjects, The invention also relates to the kit for detecting early hepatic encephalopathy paints for diagnosis subjects, by detecting relative concentration of the amine metabolism marker in serum of the diagnosis subjects, based on a binary logistic regression equation to calculate combination marker variate Prob and estimate intercept point value, so that whether the diagnosis subject is early hepatic encephalopathy paint or not can be determined. The kit has the characteristics of low detection cost and good stability. The kit can be used for clinical diagnosis for early hepatic encephalopathy, and has characteristics of high diagnostic specificity and high sensitivity, has characteristics of complementation with traditional clinical diagnostic marker blood ammonia, and has high development and application values.

The present invention relates to bio-secure means for the detection of pathogens and provides a bio-secure reaction vessel and methods of preparing a sample for PCR-based pathogen detection. The reaction vessel comprises a reaction chamber portion (1); a cap holder portion (2); and a cap (3). Two points of security, such as two O-ring seals (9, 10), are provided between the cap (3) and the reaction chamber portion (1). A first seal (9) may be located at a top of the cap holder portion (2) and a second seal (10) may be located at a base of the cap (10).

The invention relates to short-chain polypeptides PCP4 capable of being specifically bound to prostate cancer cells and an application of the short-chain polypeptides PCP4 and provides a series of polypeptides obtained through screening with a phage display peptide library technology and having a prostate cancer targeting characteristic. The binding polypeptides have high specificity and can be applied to general survey of high risk groups of the prostate cancer, early clinical diagnosis of the prostate cancer and evaluation of a treatment effect.

The invention discloses a kit for detecting or assisting in detecting ethambutol resistance of multiple drugs resistant bacillus tuberculosis. The kit comprises a product for detecting an embB354 mutation site in an embB gene, wherein the nucleotide sequence of the embB gene is the sequence 1 shown in a sequence table; and the embB354 mutation site is that nucleotide GAC from the 1060th site to the 1062nd site at the 1-5' ends of the sequences in the sequence table is mutated into GCC. Tests show that the new mutation site embB354 of the embB gene can be used for detecting the ethambutol resistance of the multiple drugs resistant bacillus tuberculosis, and the mutation site embB354 is combined with another three mutation sites, namely, embB306, embB406 and embB497, to detect the ethambutol resistance of the multiple drugs resistant bacillus tuberculosis together so as to ensure higher diagnosis sensitivity.

The present invention relates to a pleural effusion metabolite combination, a kit and a method for diagnosing tuberculous pleurisy, the pleural effusion metabolite combination for diagnosing tuberculous pleurisy comprising dimethylglycine, tyrosine, kynurenine, and nicotinamide , betaine, acylcarnitine 12:0, acylcarnitine 14:2 and phosphatidylcholine 42:8. Kit for the diagnosis of tuberculous pleurisy, including for the detection of dimethylglycine, tyrosine, kynurenine, nicotinamide, betaine, acylcarnitine 12:0, acylcarnitine 14 in the extraction solution of pleural fluid samples :2 and Phosphatidylcholine 42:8 are the required internal standards. Through the combined markers involved in the present invention, the diagnosis of tuberculous pleurisy can be characterized with high sensitivity and high specificity. At the same time, the combined marker can be complementary to the traditional marker adenosine deaminase, and combined use can be used for auxiliary diagnosis of tuberculous pleurisy.

The invention provides an oligopeptide capable of performing specificity conjugation with lung carcinoma cells. The oligopeptide provided by the invention is high in conjugation specificity with the lung carcinoma cells, and can be used for early-phase clinical diagnosis and evaluation and prognostic judgment of a treatment effect.

The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.